ISPR shifts to execution phase following a 33% Q4 revenue jump and the acquisition of key Malaysian manufacturing licenses, despite full-year margin pressures and legacy write-offs.
Q4 revenue grew 33% YoY and critical Malaysia licenses were obtained, but full-year revenue declined and gross margin fell to 6.3%.
ISPR posted a 33% year-over-year revenue increase in Q4, signaling a pivot from balance sheet restructuring to operational execution. The company secured critical nicotine manufacturing licenses in Malaysia, positioning itself to capture demand from global tobacco majors and Chinese brands seeking to diversify supply chains.
The licenses allow ISPR to produce nicotine products in Malaysia, changing the business economics and enabling the company to serve global tobacco majors and Chinese brands looking to offshore production.
The decline was primarily attributed to a specific inventory impairment recognized during the fourth quarter.